Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue (Q33195235)

23 July 2017

title

Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue (English)

1 reference

23 July 2017

Joerg Fellenberg

1

1 reference

23 July 2017

Alexandra Krauthoff

2

1 reference

23 July 2017

Konstantin Pollandt

3

1 reference

23 July 2017

Guenter Delling

4

1 reference

23 July 2017

Dominik Parsch

5

1 reference

23 July 2017

publication date

1 January 2004

1 reference

23 July 2017

published in

Laboratory Investigation

1 reference

23 July 2017

volume

84

1 reference

23 July 2017

issue

1

1 reference

23 July 2017

page(s)

113-121

1 reference

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Tumor size and prognosis in aggressively treated osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Quantitative molecular analysis of laser-microdissected paraffin-embedded human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Laser capture microdissection in pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Laser-mediated microdissection of paraffin sections from Xenopus embryos allows detection of tissue-specific expressed mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

Osteogenic sarcoma with clinically detectable metastasis at initial presentation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

Treatment of osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group (COSS)

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

1 reference

7 January 2021

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

Tissue microdissection techniques in quantitative genome and gene expression analyses.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700006

7 January 2021

10.1038/LABINVEST.3700006

Identifiers

DOI

1 reference

Dimensions Publication ID

23 July 2017

1039109594

0 references

Fatcat ID

release_zmlbzmu6yfgxtc74ehigy7dehq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zmlbzmu6yfgxtc74ehigy7dehq

24 November 2022

mapped directly with Wikidata item

1 reference